The Effect of Cilostazol on Glucose Tolerance and Insulin Resistance in a Rat Model of Non-insulin Dependent Diabetes Mellitus

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2001 Oct 10

PMID 11590907

Citations 5

Authors

S A Chang

B Y Cha

S J Yoo

Y B Ahn

K H Song

J H Han

J M Lee

H S Son

K H Yoon

M I Kang

K W Lee

H Y Son

S K Kang

Affiliations

Soon will be listed here.

Abstract

Background: It has been reported that many peripheral vasodilating drugs might improve insulin resistance. Cilostazol, a antithrombotic agent, increases peripheral blood flow in non-insulin dependent diabetic patients. The effect of cilostazol treatment on insulin resistance in streptozotocin (STZ)-induced non-insulin dependent diabetic Wistar rats was examined.

Methods: About a half of two-day old neonate siblings were injected intraperitoneally with STZ and maintained for six months, at which time they were compared with age-matched control rats for intraperitoneal glucose tolerance test (IPGTT) and for glucose infusion rate (GINF) in a euglycemic hyperinsulinemic glucose-clamp study. After that, these studies were also performed after feeding rat chow containing cilostazol (100 mg/kg/day) to rats with STZ-induced non-insulin dependent diabetes mellitus for four-weeks and compared with those of age-matched control rats.

Results: In the intraperitoneal glucose tolerance test studies, plasma glucose levels of STZ-induced non-insulin dependent diabetic rats were significantly higher and plasma insulin levels significantly lower than those of age-matched control rats in the age of six months. Glucose infusion rate was lower in STZ-induced non-insulin dependent diabetic rats than those of age-matched control rats. However, after a four-week cilostazol treatment, glucose infusion rate of STZ-induced non-insulin dependent diabetic rats was not significantly different from that of control rats.

Conclusion: These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats.

Citing Articles

A Review of Antidiabetic Medicinal Plants as a Novel Source of Phosphodiesterase Inhibitors: Future Perspective of New Challenges Against Diabetes Mellitus.

Ouassou H, Daoudi N, Bouknana S, Abdnim R, Bnouham M Med Chem. 2024; 20(5):467-486.

PMID: 38265379 DOI: 10.2174/0115734064255060231116192839.

Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice.

Seo D, Shin E, Lee Y, Park S, Nam K, Kim J Biomedicines. 2022; 10(8).

PMID: 36009398 PMC: 9405663. DOI: 10.3390/biomedicines10081852.

Role of Phosphodiesterase in the Biology and Pathology of Diabetes.

Kilanowska A, Ziolkowska A Int J Mol Sci. 2020; 21(21).

PMID: 33153226 PMC: 7662747. DOI: 10.3390/ijms21218244.

Cilostazol attenuates the severity of peripheral arterial occlusive disease in patients with type 2 diabetes: the role of plasma soluble receptor for advanced glycation end-products.

Liu J, Chuang T, Chen J, Lee C, Hsieh C, Lin T Endocrine. 2015; 49(3):703-10.

PMID: 25666934 PMC: 4512567. DOI: 10.1007/s12020-015-0545-6.

Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.

Sun H, Lee Y, Han K, Kim H, Ahn S, Han S Korean J Intern Med. 2012; 27(2):163-70.

PMID: 22707888 PMC: 3372800. DOI: 10.3904/kjim.2012.27.2.163.

References

Lonnroth P, Davies J, Lonnroth I, Smith U . The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic-AMP-dependent and -independent mechanisms. Biochem J. 1987; 243(3):789-95. PMC: 1147926. DOI: 10.1042/bj2430789. View

Makino H, Suzuki T, KAJINUMA H, Yamazaki M, Ito H, Yoshida S . The role of insulin-sensitive phosphodiesterase in insulin action. Adv Second Messenger Phosphoprotein Res. 1992; 25:185-99. View

Schaffer S, Wilson G . Insulin resistance and mechanical dysfunction in hearts of Wistar rats with streptozotocin-induced non-insulin-dependent diabetes mellitus. Diabetologia. 1993; 36(3):195-9. DOI: 10.1007/BF00399949. View

KARL I, Gavin 3rd J, Levy J . Effect of insulin on glucose utilization in epitrochlearis muscle of rats with streptozocin-induced NIDDM. Diabetes. 1990; 39(9):1106-15. DOI: 10.2337/diab.39.9.1106. View

Portha B, Picon L, Rosselin G . Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia. 1979; 17(6):371-7. DOI: 10.1007/BF01236272. View

Wesslau C, Eriksson J, Smith U . Cellular cyclic AMP levels modulate insulin sensitivity and responsiveness--evidence against a significant role of Gi in insulin signal transduction. Biochem Biophys Res Commun. 1993; 196(1):287-93. DOI: 10.1006/bbrc.1993.2247. View

Nishi T, Tabusa F, Tanaka T, Shimizu T, Kanbe T, Kimura Y . Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull (Tokyo). 1983; 31(4):1151-7. DOI: 10.1248/cpb.31.1151. View

Jauch K, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G . Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 1987; 17(5):448-54. DOI: 10.1111/j.1365-2362.1987.tb01141.x. View

Blondel O, Bailbe D, Portha B . Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism. 1990; 39(8):787-93. DOI: 10.1016/0026-0495(90)90120-2. View

10.

Pollare T, Lithell H, Selinus I, Berne C . Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988; 31(7):415-20. DOI: 10.1007/BF00271585. View

11.

DeFronzo R, Jacot E, Jequier E, MAEDER E, Wahren J, Felber J . The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes. 1981; 30(12):1000-7. DOI: 10.2337/diab.30.12.1000. View

12.

Portha B, Blondel O, Serradas P, McEvoy R, Giroix M, Kergoat M . The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabete Metab. 1989; 15(2):61-75. View

13.

Weir G, Clore E, Zmachinski C, Bonner-Weir S . Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes. 1981; 30(7):590-5. DOI: 10.2337/diab.30.7.590. View

14.

Trent D, Fletcher D, May J, Bonner-Weir S, Weir G . Abnormal islet and adipocyte function in young B-cell-deficient rats with near-normoglycemia. Diabetes. 1984; 33(2):170-5. DOI: 10.2337/diab.33.2.170. View

15.

Okuda Y, Mizutani M, Ikegami T, Ueno E, Yamashita K . Hemodynamic effects of cilostazol on peripheral artery in patients with diabetic neuropathy. Arzneimittelforschung. 1992; 42(4):540-2. View

16.

Bjorntorp P, Berchtold P, Holm J, Larsson B . The glucose uptake of human adipose tissue in obesity. Eur J Clin Invest. 1971; 1(6):480-5. DOI: 10.1111/j.1365-2362.1971.tb00559.x. View

17.

Fantus I, Chayoth R, ODea L, Marliss E, Yale J, Grose M . Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Diabetes. 1987; 36(5):654-60. DOI: 10.2337/diab.36.5.654. View

18.

Hagstrom-Toft E, Bolinder J, Eriksson S, Arner P . Role of phosphodiesterase III in the antilipolytic effect of insulin in vivo. Diabetes. 1995; 44(10):1170-5. DOI: 10.2337/diab.44.10.1170. View

19.

DeFronzo R, Ferrannini E, Hendler R, FELIG P, Wahren J . Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia in man. Diabetes. 1983; 32(1):35-45. DOI: 10.2337/diab.32.1.35. View

20.

Kamiya T, Sakaguchi S . Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimittelforschung. 1985; 35(7A):1201-3. View